Jonna S, Feldman RA, Swensen J, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25(16):4966-4972. doi:10.1158/1078-0432.CCR-18-4049
Gay ND, Kim S, Dai J, et al. NRG1 gene fusions in breast cancer. Clin Cancer Res. 2017;23(24):7146-7152. doi:10.1158/1078-0432.CCR-17-1344
Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74–NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4(4):415-422. doi:10.1158/2159-8290.CD-13-0633
Drilon A, Cappuzzo F, Ou SI, et al. Targeting NRG1 fusions in cancer. Nat Rev Clin Oncol. 2021;18(1):11-27. doi:10.1038/s41571-020-0414-3
Odintsov I, Lui AJW, Sisso WJ, et al. High prevalence of NRG1 fusions in invasive mucinous adenocarcinoma of the lung. Clin Cancer Res. 2020;26(17):4427-4434. doi:10.1158/1078-0432.CCR-20-0201
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
